Search Bar & Filters
Found 8 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating how tirzepatide affects body weight and cardiovascular risk factors in adolescents with obesity who have multiple related health conditions. This Phase 3 study focuses on the safety and effectiveness of tirzepatide compared to a placebo, combined with healthy nutrition and physical activity. The study is sponsored by Eli Lilly and Company and aims to provide insights for treating obesity and its complications in teenagers aged 12 to 17. Participants are randomly assigned to receive either tirzepatide or a placebo through subcutaneous injections once weekly. The main treatment period lasts up to 72 weeks, during which participants also follow a lifestyle intervention focused on diet and exercise. Those who completed a prior related study within the last 12 weeks may continue with an additional 156 weeks of tirzepatide treatment alongside ongoing lifestyle support. Throughout the study, participants attend up to 23 visits over approximately 76 weeks. Researchers will monitor changes in body mass index BMI, weight-related comorbidities, blood sugar control HbA1c, blood pressure, body fat, and other health markers. Safety assessments and questionnaires will be conducted regularly to track health status and treatment adherence. The study seeks to understand how tirzepatide influences both weight and cardiovascular risk factors over time in this adolescent group.
Actively Recruiting
Researchers are studying severe alopecia areata AA, a condition where the immune system attacks hair follicles causing hair loss on the scalp and face, in pediatric patients aged 6 to under 18 years. The study evaluates the safety and effectiveness of upadacitinib, an investigational Janus-Kinase JAK inhibitor, compared to placebo. This phase 3, randomized, double-blind, placebo-controlled trial addresses the need for systemic treatments approved for young patients, as current options may not work or lose effectiveness over time. Participants are randomly assigned to one of three groups two different doses of upadacitinib or a matching placebo. The study lasts approximately 160 weeks and includes a 35-day screening period, a 24-week placebo-controlled treatment phase Period A, a 28-week blinded extension Period B, a 108-week long-term extension Period C, and a 30-day follow-up. Those initially on placebo who do not achieve sufficient hair regrowth may switch to upadacitinib during the extension periods. During the study, participants attend regular hospital or clinic visits for medical assessments, blood tests, questionnaires, and side effect monitoring. The main outcome measured is the percentage of participants achieving a Severity of Alopecia Tool SALT score indicating 20% or less scalp hair loss at Week 24. Researchers also track adverse events through Week 160 and assess other measures related to hair loss, quality of life, anxiety, and depression. Participants adherence and safety are closely monitored throughout the long study duration.
Actively Recruiting
Alopecia areata AA is a condition where the immune system attacks hair follicles, causing hair loss typically on the head and face but potentially on any body part. This research aims to evaluate the safety, effectiveness, and tolerability of upadacitinib tablets in adolescents and adults with severe AA. The study involves multiple phases to assess different doses of upadacitinib compared to placebo. Participants are randomly assigned to one of three treatment groups receiving either upadacitinib Dose A, Dose B, or placebo tablets daily. Those on placebo may be re-randomized to upadacitinib groups depending on their Severity of Alopecia Tool SALT score at Week 24. The study includes periods A and B lasting up to 52 weeks each, with some participants continuing treatment for up to 108 weeks in an extension phase. The trial enrolls about 1500 participants worldwide. During the study, participants take oral tablets daily and attend regular visits at clinics or hospitals. Their response to treatment is monitored through medical assessments, blood tests, questionnaires, and side effect checks. The main outcomes measured include changes in SALT scores and recording adverse events over approximately 164 weeks. Follow-up occurs for up to 30 days after the last dose to monitor safety and treatment effects.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of FB102 in adults with severe to very severe alopecia areata, a condition causing significant hair loss. This randomized, double-blind, placebo-controlled Phase 1 study aims to better understand how FB102 works compared to a placebo in this patient group. Up to 32 participants will be randomly assigned in a 3 to 1 ratio to receive either FB102 or a matching placebo. Both treatments are given intravenously. The study will monitor participants over several weeks, assessing safety and changes in hair loss severity. Participants will be involved in the study for up to 36 weeks after their first dose. During this time, they will undergo regular evaluations including tracking treatment-related side effects and measuring changes in hair loss using the Severity of Alopecia Tool SALT score. Researchers will carefully monitor safety and treatment responses throughout the study.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety, how the body processes, and the effects of a new drug called TRB-061, given as injections under the skin, in healthy adults and people with moderate-to-severe atopic dermatitis AD. This Phase 1a1b study includes healthy volunteers and patients to explore different dosing schedules and amounts in a randomized, double-blind, placebo-controlled setting. The study has three parts Part 1 involves healthy adults receiving a single dose of TRB-061 or placebo Part 2 includes healthy adults receiving three doses every 4 weeks over 8 weeks and Part 3 involves participants with moderate-to-severe AD receiving four doses every 4 weeks over 12 weeks. In Part 3, participants may also opt to switch treatments after the first period. Placebo doses match the appearance and schedule of TRB-061. Participants will attend multiple visits for dosing and follow-up, including safety checks, blood tests to measure drug levels, and assessments of side effects up to 12 weeks after dosing in Part 1, 10 weeks after dosing in Part 2, and through the end of the study in Part 3. Researchers will track adverse events, drug levels in the blood, and responses to treatment during the study, which runs until early 2028.
Actively Recruiting
Researchers are evaluating the safety, tolerability, pharmacokinetics, and immune response of PRA-216 compared to a placebo in adults with moderate to severe Atopic Dermatitis AD. This Phase 2 study includes patients whose AD is not well controlled by topical corticosteroids or who have had adverse reactions or cannot use such medications. Approximately 39 participants will take part in this multicenter, randomized, double-blind, placebo-controlled trial. Participants will be randomly assigned in a 21 ratio to receive either PRA-216 or a matching placebo via subcutaneous injections. Each participant will receive four injections during the study period. The study is designed to observe and compare the effects of PRA-216 and placebo on AD symptoms and safety measures. Throughout the study, participants will attend multiple visits for monitoring. Researchers will assess treatment-emergent adverse events and serious adverse events for up to 28 weeks. They will also evaluate clinical responses using measures such as EASI-75 and EASI-90 scores for up to 24 weeks. Pharmacokinetics parameters like Tmax, AUC, and Cmax, as well as immunogenicity, will be monitored. The total study duration extends to May 2028.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating whether expanding the use of finger-stick point-of-care testing for hepatitis C virus HCV can improve diagnosis and treatment rates among people at risk for HCV infection. This observational cohort study is conducted by the Kirby Institute and aims to support Australias goal of eliminating HCV by 2030 amid challenges such as declining treatment uptake and impacts from COVID-19. The study focuses on populations with risk factors, including those attending drug treatment clinics, needle and syringe programs, prisons, and other community services. Participants will attend a single visit where they will receive point-of-care HCV antibody testing, providing results within 1 to 20 minutes. If antibody positive, a further point-of-care HCV RNA test will be done to detect active infection. Those with previous HCV infection or treatment will be tested directly with the HCV RNA test. The study does not provide treatment, but participants testing positive for HCV RNA will be connected to standard care pathways for treatment initiation and further clinical evaluation. During the visit, participants will also complete a self-administered survey. Researchers will link survey responses to administrative data to assess long-term health outcomes and the impact of testing scale-up. The primary outcome is the proportion of participants who start HCV treatment within 12 weeks after testing positive. Secondary outcomes include treatment uptake timing, completion rates, cure rates, and cost-effectiveness of testing strategies. Participation involves only one visit, but follow-up data will be collected through linkage to health records over time.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating whether increasing the use of finger-stick point-of-care testing for hepatitis C virus HCV infection can improve diagnosis and treatment rates. The study is observational and focuses on people at risk for HCV infection who access services such as drug treatment clinics, needle and syringe programs, homelessness support, mental health services, prisons, and mobile outreach. The goal is to support national and state strategies aiming to eliminate HCV by 2030 by improving testing and treatment uptake. Participants will be offered point-of-care HCV RNA testing through finger-stick blood samples at various service sites. This testing approach allows for quicker diagnosis by reducing the need for multiple clinic visits. The program includes training for operators, quality assurance, and logistics for scaling up testing across different community health settings. Participants do not receive treatment within the study but those testing positive for HCV RNA will be connected to standard care for further assessment and treatment. During the study, participants will undergo point-of-care testing, and data will be collected on testing acceptance, HCV prevalence, and treatment initiation and completion. Researchers will measure the proportion of infected participants who start treatment within 12 weeks and track treatment outcomes up to 12 months. The study will run until 2029, and participants involvement focuses on testing and monitoring outcomes rather than receiving study treatments directly.